share_log

Further Weakness as Shenzhen Chipscreen Biosciences (SHSE:688321) Drops 5.8% This Week, Taking Five-year Losses to 64%

Further Weakness as Shenzhen Chipscreen Biosciences (SHSE:688321) Drops 5.8% This Week, Taking Five-year Losses to 64%

进一步疲软,微芯生物(SHSE:688321)本周下跌5.8%,五年损失达到64%.
Simply Wall St ·  2024/12/20 09:20

It is doubtless a positive to see that the Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) share price has gained some 31% in the last three months. But that can't change the reality that over the longer term (five years), the returns have been really quite dismal. The share price has failed to impress anyone , down a sizable 64% during that time. So we're hesitant to put much weight behind the short term increase. However, in the best case scenario (far from fait accompli), this improved performance might be sustained.

毫无疑问,看到微芯生物(上海证券交易所代码:688321)的股价在过去三个月上涨了31%,这是件好事。但这并不能改变一个事实,即在更长期(五年)来看,回报实在是相当糟糕。在这段时间内,股价下跌了64%,让人失望。因此,我们对短期增长持谨慎态度。然而,在最理想的情况下(远非必然),这种改善的表现可能会持续下去。

After losing 5.8% this past week, it's worth investigating the company's fundamentals to see what we can infer from past performance.

在过去一周下跌了5.8%之后,值得对公司的基本面进行调查,以看看我们能从过去的表现中得出什么结论。

Because Shenzhen Chipscreen Biosciences made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Shareholders of unprofitable companies usually desire strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings.

由于微芯生物在过去的十二个月里出现了亏损,我们认为市场可能更关注营业收入和营业收入的增长,至少现在是这样。没有盈利的公司的股东通常希望看到强劲的营业收入增长。有些公司愿意推迟盈利以更快地增长营业收入,但在这种情况下,人们希望能够看到良好的营业收入增长,以弥补缺乏收益的不足。

Over five years, Shenzhen Chipscreen Biosciences grew its revenue at 24% per year. That's better than most loss-making companies. In contrast, the share price is has averaged a loss of 10% per year - that's quite disappointing. It's safe to say investor expectations are more grounded now. If you think the company can keep up its revenue growth, you'd have to consider the possibility that there's an opportunity here.

在五年里,微芯生物的营业收入每年增长24%。这比大多数亏损公司要好。相比之下,股价平均每年下降10%,这令人相当失望。可以坦率地说,投资者的期望现在更加务实了。如果你认为这家公司能够保持其营业收入增长,你就必须考虑这里存在机会的可能性。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下面的图表显示了收益和营收随时间的变化情况(通过单击图像揭示确切的值)。

big
SHSE:688321 Earnings and Revenue Growth December 20th 2024
SHSE:688321 2024年12月20日的盈利和营业收入增长

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

您可以通过这个免费的互动图形查看其资产负债表随时间的增强(或减弱)。

A Different Perspective

不同的视角

Investors in Shenzhen Chipscreen Biosciences had a tough year, with a total loss of 8.4%, against a market gain of about 14%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, longer term shareholders are suffering worse, given the loss of 10% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. It's always interesting to track share price performance over the longer term. But to understand Shenzhen Chipscreen Biosciences better, we need to consider many other factors. For instance, we've identified 1 warning sign for Shenzhen Chipscreen Biosciences that you should be aware of.

Investors in Shenzhen Chipscreen Biosciences had a tough year, with a total loss of 8.4%, against a market gain of about 14%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, longer term shareholders are suffering worse, given the loss of 10% doled out over the last five years. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. It's always interesting to track share price performance over the longer term. But to understand Shenzhen Chipscreen Biosciences better, we need to consider many other factors. For instance, we've identified 1 warning sign for Shenzhen Chipscreen Biosciences that you should be aware of.

But note: Shenzhen Chipscreen Biosciences may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

But note: Shenzhen Chipscreen Biosciences may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文中引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发